65,437 trials
Multiple Myeloma
Primary: Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set) — 334 Participants — p=<0.0001
Asthma
Primary: FeNO Values by ACT Score — 40.3; 26.3 parts per billion (ppb)
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Metastatic, Androgen Independent Prostate Cancer · Prostate Cancer
Primary: Number of Patients Free of Dose Limiting Toxicity — 14 participants
Healthy
Primary: Radiographic Densities at Selected Regions in Contrast-enhanced CT Examination by Location (Abdominal Aorta), kVp 80 and Contrast Type (Ioforminol vs Iopamidol)…
Irritable Bowel Syndrome
Primary: Colonic Compliance — 18.96; 16.86; 15.99; 15.75 mm Hg
Catheterization (Clean, Intermittent Urinary Catheterization)
Primary: Number of Participants With Discomfort — 15; 29 participants — p=0.0066
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels — 5 percentage of participants
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 — -10.49; -14.30 scores on a scale — p=<0.001
Prostate Cancer
Primary: Overall Response Rate — 6 percentage of patients
Keratoconjunctival Epithelial Disorder
Primary: Change in the Keratoconjunctival Staining Score From Baseline — -3.4; -3.1 scores on a scale — p=0.576
Non-small Cell Lung Cancer
Primary: Response Rates Confirmed With CT or MRI — 64.6 percentage of participants
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 53.2 percentage of participants
HIV
Primary: Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Load <50 Copies/Milliliter (mL) at 48 Weeks. — 77.92 Percentage of…